Abstract:
This disclosure describes compositions of matter useful as growth inhibitors of transplanted tumors in mammals; and this invention discloses a method of inducing the regression and/or palliation of various types of tumors in mammals and which are susceptible to treatment by certain substituted phenoxy dimethyl alkanoic acids, esters or salts, said method comprising giving to said mammals an effective amount of a compound of the following formula: ##STR1## [wherein A represents an imidazolyl group or a pyridyl group,l represents 0 or 1,m and n each, which may be the same or different, represents an integer of 1 to 6, and,R represents a hydrogen atom or a lower alkyl group],or a salt thereof; the invention also discloses a method of inhibition (or prevention) of metastasis of the various cancers.The above formula compounds have low toxicity, and it is expected to apply various types of administration thereof such as oral administration and parenteral administration.
Abstract:
This disclosure describes compositions of matter useful as growth inhibitors of transplanted tumors in mammals: and this invention discloses a method of inducing the regression and/or palliation of various types of tumors in mammals (mammary cancer, liver cancer, skin cancer, etc.), said method comprising giving to said mammals an effective amount of a compound of the following formula: ##STR1## [wherein A represents an imidazolyl group or a pyridyl group, l represents 0 or 1, m and n each, which may be the same of different, represents an integer of 1 to 6, and, R represents a hydrogen atom or a lower alkyl group], or a salt thereof; the invention also discloses a method of inhibition (or prevention) of metastasis of the various cancers.The above formula compounds have low toxicity, and it is expected to apply various types of administration thereof such as oral administration and parenteral administration. In particular, it is expected that the compounds are useful as new type of medical (anti-cancer) compounds which can be administered orally.
Abstract:
Novel phenoxy derivatives are provided such as 6-[p-5-(1-imidazolyl)pentyloxy]phenoxy]-2,2-dimethyl-hexanoic acid, pharmaceutical compositions containing the derivative and their use in treating tumors.
Abstract:
Novel phenoxy derivatives are provided which can be represented by the general formula: ##STR1## wherein the various substituents are as defined, and include compounds such as benzyl 6-[p-[5-(1-imidazolyl)pentyloxy]phenoxy]-2,2-dimethylhexanoate.The invention also encompasses pharmaceutical compositions containing the derivatives and their use in treating tumors.
Abstract:
A printing control device includes: a banner data detecting unit that detects banner data from print data; a data acquiring unit that acquires, when the banner data are detected by the banner data detecting unit, data for designating a printing condition for printing a text located after the banner data in the print data; and a printing condition setting unit that sets, when the data for designating the printing condition for printing the text are acquired by the data acquiring unit, the printing condition as a printing condition for printing the print data.
Abstract:
Osteoporosis and the like metabolic bone diseases have a high frequency of causing lumbago and the like pains and bone fracture, due to lowering of the bone strength caused by the reduction of bone mass. Accordingly, great concern has been directed toward the creation of a drug which can increase the bone mass and bone strength by controlling the whole bone metabolism. The pharmaceutical composition or combination product of the invention comprising a non-living body-derived non-peptide osteoblast differentiation promoting compound and a bisphosphonate having a bone resorption inhibitory action is useful as a bone mass increasing inducer which can increase the bone mass and/or bone strength by controlling the bone metabolism.
Abstract:
In an optical disc apparatus, a minimum jitter value is established from each jitter value measured in correspondence to a successively changed servo constant, and multiplied by a prescribed ratio so as to set a jitter threshold value. Servo constants corresponding to at least two jitter values substantially equal to the jitter threshold value is established, and an optimum servo constant is set based on this minimum of two servo constants. By doing this, it is possible to quickly and accurately detect the optimum servo constant, and achieve good servo adjustment.
Abstract:
A bone-forming graft that includes a bone morphogenetic protein (BMP) carried on a composite porous body. The composite porous body has a porous frame of a bioabsorbable hydrophilic material and a surface layer of a bioabsorbable polymer material. In particular, the present invention relates to a bone-forming graft in which the bioabsorbable hydrophilic material is one or more compounds selected from a group consisting of gelatin, hyaluronic acid, a hyaluronic acid derivative, collagen, a collagen derivative, chitosan, a chitosan derivative, and triethanolamine alginate. The bioabsorbable polymeric material is one or more compounds selected from a group consisting of a polylactic acid, a copolymer of a polylactic acid and a polyglycolic acid, and a copolymer of poly�bis(p-carboxyphenoxy)propane!anhydride and sebacic acid. The graft has excellent formability and workability and has an internal structure suitable for in vivo bone formation. Bone formation occurs not only at the periphery of the graft but also within the graft.
Abstract:
The present invention provides a clasp assembly for a metallic watch chain, mainly comprising: an inner bend plate, an outer bend plate, and a clasp cap. Said inner bend plate can fit into the narrow groove of the outer bend plate. A convex clasp is disposed on the inner bend plate and corresponds to a concave clasp disposed on the outer bend plate in shape, position and size, and the two clasps engage with each other. The lock and release of the convex and concave clasps causes the lock and release of the watch chain. The clasp cap pivotably connects with the inner bend plate through screws. The hole of the clasp cap connects with the watch chain, and the outer bend plate connects with the watch chain through the cylindrical bodies at the left end. The structure of the clasp assembly is simple and is easy to use.
Abstract:
An epitaxial wafer for a GaP pure green light emitting diode includes an n-type single crystal GaP substrate formed in order thereon with a first n-type GaP epitaxial layer, a second n-type GaP epitaxial layer and a p-type GaP epitaxial layer. The p-type GaP epitaxial layer has a sulfur concentration of not greater than 1.times.10.sup.17 cm.sup.31 3, the second n-type GaP epitaxial layer has a carrier concentration on a side thereof interfacing with the p-type GaP epitaxial layer of 0.5-5.times.10.sup.17 cm.sup.-3, and the p-type GaP epitaxial layer has a carrier concentration on a side thereof interfacing with the second n-type GaP epitaxial layer that is 1-10.times.10.sup.17 cm.sup.-3 and is not less than twice the carrier concentration of the second n-type GaP epitaxial layer on the side thereof interfacing with the p-type GaP epitaxial layer. A GaP pure green light-emitting diode exhibiting high brightness includes the epitaxial wafer, an n-type electrode provided on a back surface of the single crystal substrate and a p-type electrode provided on the upper surface of the p-type GaP epitaxial layer.
Abstract translation:用于GaP纯绿色发光二极管的外延晶片包括依次形成有第一n型GaP外延层,第二n型GaP外延层和p型GaP外延层的n型单晶GaP衬底 。 p型GaP外延层的硫浓度不大于1×10 17 cm -3 3 3,第二n型GaP外延层在其与p型GaP外延层接合的一侧上具有0.5-5×10 17 cm -1的GaP外延层, 3,并且p型GaP外延层在其与第二n型GaP外延层接合的一侧上的载流子浓度为1-10×10 17 cm -3,并且不小于第二n-型GaP外延层的载流子浓度的两倍, GaP外延层与p型GaP外延层接合。 显示高亮度的GaP纯绿色发光二极管包括外延晶片,设置在单晶衬底的背面上的n型电极和设置在p型GaP外延层的上表面上的p型电极 。